Another write-up about ZEN-3694.

• patients in the trial whose tumors didn’t respond well to androgen receptor inhibitors prior to study enrollment appeared to have the most durable control with ZEN-3694, suggesting the most aggressive tumors may be particularly susceptible to BET bromodomain inhibition.

This write-up is basically very similar to what I posted the other day.

BET Inhibitors may help Overcome a Newly Recognized Form of Resistance to Prostate Cancer Drugs - Onco'Zine (oncozine.com)

At least it seems there is some talk going on about Zenith.

masila